EP1571926A1 - Use of prebiotics for preventing or treating oxidation stress - Google Patents
Use of prebiotics for preventing or treating oxidation stressInfo
- Publication number
- EP1571926A1 EP1571926A1 EP03813628A EP03813628A EP1571926A1 EP 1571926 A1 EP1571926 A1 EP 1571926A1 EP 03813628 A EP03813628 A EP 03813628A EP 03813628 A EP03813628 A EP 03813628A EP 1571926 A1 EP1571926 A1 EP 1571926A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- fructose
- oligosaccharides
- prebiotics
- fos
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 28
- 230000003647 oxidation Effects 0.000 title abstract description 3
- 238000007254 oxidation reaction Methods 0.000 title abstract description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract description 76
- 239000005715 Fructose Substances 0.000 claims abstract description 43
- 229930091371 Fructose Natural products 0.000 claims abstract description 29
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 230000036542 oxidative stress Effects 0.000 claims description 31
- 229920001542 oligosaccharide Polymers 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 14
- 230000002265 prevention Effects 0.000 claims description 11
- 150000002482 oligosaccharides Chemical class 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 8
- 150000003254 radicals Chemical class 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 235000000346 sugar Nutrition 0.000 claims description 7
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 229920002670 Fructan Polymers 0.000 claims description 5
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 5
- 150000008163 sugars Chemical class 0.000 claims description 5
- QNTKVQQLMHZOKP-NEJDVEAASA-N (2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-2-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxymethyl]- Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QNTKVQQLMHZOKP-NEJDVEAASA-N 0.000 claims description 3
- VAWYEUIPHLMNNF-OESPXIITSA-N 1-kestose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 VAWYEUIPHLMNNF-OESPXIITSA-N 0.000 claims description 3
- GIUOHBJZYJAZNP-DVZCMHTBSA-N 1-kestose Natural products OC[C@@H]1O[C@](CO)(OC[C@]2(O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)O[C@@H](O)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O GIUOHBJZYJAZNP-DVZCMHTBSA-N 0.000 claims description 3
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- VAWYEUIPHLMNNF-UHFFFAOYSA-N kestotriose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 VAWYEUIPHLMNNF-UHFFFAOYSA-N 0.000 claims description 3
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 claims description 3
- 230000003712 anti-aging effect Effects 0.000 claims description 2
- 230000001681 protective effect Effects 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 abstract description 9
- 235000014633 carbohydrates Nutrition 0.000 abstract description 8
- 235000013376 functional food Nutrition 0.000 abstract 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 16
- 235000005911 diet Nutrition 0.000 description 16
- 230000037213 diet Effects 0.000 description 15
- 229920002472 Starch Polymers 0.000 description 14
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019165 vitamin E Nutrition 0.000 description 9
- 239000011709 vitamin E Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 229940046009 vitamin E Drugs 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 150000003626 triacylglycerols Chemical class 0.000 description 7
- 238000000540 analysis of variance Methods 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- BJHIKXHVCXFQLS-UYFOZJQFSA-N fructose group Chemical group OCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 241000894007 species Species 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003244 pro-oxidative effect Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZFTFOHBYVDOAMH-XNOIKFDKSA-N (2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-5-[[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxymethyl]-3,4-dihydroxy-2-(hydroxymethyl)oxolan-2-yl]oxymethyl]-2-(hydroxymethyl)oxolane-2,3,4-triol Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(OC[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 ZFTFOHBYVDOAMH-XNOIKFDKSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- RNBGYGVWRKECFJ-ARQDHWQXSA-N beta-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ARQDHWQXSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229950005392 fosfructose Drugs 0.000 description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 230000006099 transfructosylation Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- YJGAQZSJEQXYGO-JTIPTFDKSA-N (3S,4R,5R)-1-[(3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OCC1([C@@H](O)[C@H](O)[C@H](O1)CO)C(O)C(=O)[C@@H](O)[C@H](O)[C@H](O)CO YJGAQZSJEQXYGO-JTIPTFDKSA-N 0.000 description 1
- KVJHGPAAOUGYJX-UHFFFAOYSA-N 1,1,3,3-tetraethoxypropane Chemical compound CCOC(OCC)CC(OCC)OCC KVJHGPAAOUGYJX-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- ZCLAHGAZPPEVDX-UHFFFAOYSA-N D-panose Natural products OC1C(O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC1COC1C(O)C(O)C(O)C(CO)O1 ZCLAHGAZPPEVDX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920000884 Isomaltosaccharide Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- FHHZOYXKOICLGH-UHFFFAOYSA-N dichloromethane;ethanol Chemical compound CCO.ClCCl FHHZOYXKOICLGH-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- -1 fructose or sucrose Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 150000002402 hexoses Chemical group 0.000 description 1
- 235000019137 high fructose diet Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 1
- FBJQEBRMDXPWNX-FYHZSNTMSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)C(O)O2)O)O1 FBJQEBRMDXPWNX-FYHZSNTMSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000021140 nondigestible carbohydrates Nutrition 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- ZCLAHGAZPPEVDX-MQHGYYCBSA-N panose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ZCLAHGAZPPEVDX-MQHGYYCBSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the use of prebiotics for the preparation of food preparations, ahcaments, or pharmaceutical compositions intended for the prevention or treatment of oxidative stress.
- Oxidative stress is the result of an imbalance within the body in favor of pro-oxidant species compared to antioxidant species.
- the pro-oxidant species are generally free radicals and in particular oxygenated free radicals.
- the presence of an unpaired electron makes these compounds extremely reactive towards the biological macromolecules of the organism; lipids, carbohydrates, proteins and nucleic acids are thus privileged targets of "these species.
- the oxidative degradation of these macromolecules leads to numerous cellular dysfunctions.
- the origin of these free radicals essentially takes its source in the metabolism of Most of the oxidative stress comes from energy metabolism, so the final stage of food oxidation, the mitochondrial respiratory chain, is responsible for the formation of oxygenated free radicals. during the inflammatory reaction, stimulation of phagocytic cells is also accompanied by the formation of free radicals.
- the body's antioxidant defenses call on protein systems, such as superoxide dismutase, but also on antioxidant compounds provided by food, such as vitamins C and E, or other nutrients, like carotenoids, polyphenols or flavonoids. Dietary imbalances can be the cause of oxidative stress.
- the inventors have in particular shown previously that a diet too rich in sugars, and in particular in sucrose (Busserolles et al, 2002a) and in fructose (Busserolles et al, 2002b), could generate significant oxidative stress. These pro-oxidant effects are all the more important as the diet is depleted in antioxidants.
- Fructose is a monosaccharide whose consumption has greatly increased, either as such or in the form of sucrose. Due to their low cost of obtaining, syrups rich in fructose from corn are preferably used in sugary drinks.
- fructose is naturally present in honey and in fruits where it is associated with many protective micronutrients, one can wonder about the consequences for health, an unlimited increase in this purified carbohydrate. Indeed, fructose has many properties that distinguish it from other sugars and the high intake of this carbohydrate could be responsible for undesirable metabolic effects.
- the methods of combating oxidative stress generally involve the use of anti-free radical nutrients having a direct effect on free radicals: carotenes, ascorbic acid (vitamin C), tocopherols (vitamin E) , polyphenols (US Patent No. 6,207,702).
- the present invention stems from the discovery by the inventors of the fact that prebiotics and more particularly fructo-oligosaccharides (FOS) make it possible to combat oxidative stress resulting from an excess of fructose in the diet.
- FOS fructo-oligosaccharides
- Prebiotics are complex, non-digestible carbohydrates degraded by microorganisms. the intestinal flora, and whose degradation- is responsible for beneficial effects ⁇ for the health of the host.
- These microorganisms are generally bacteria, and in particular bifodobacteria, which are found mainly in the colon.
- the beneficial effects caused by said microorganisms may be due to the selective stimulation of the growth of certain species of microorganisms, in particular bifodobacteria, and / or to the release of metabolites resulting from the transformation of prebiotics by microorganisms.
- oligosaccharides As it stands, the only clearly defined pre-biotics are sugar polymers with a degree of polymerization between 2 and 12, classified among complex carbohydrates: oligosaccharides. Mention may thus be made, in addition to the fructo-oligosaccharides whose effects are the most documented, fructans, galacto-oligosaccharides, xylo-oligosaccharides, soy oligosaccharides, gentio-oligosaccharides or isomalto-oligosaccharides.
- Fructo-oligosaccharides are obtained either by hydrolysis of inulin, or by enzymatic synthesis, by transfructosylation from saccharide precursors. They correspond to the general formula Glucosyl- (Fructosyl) n -Fructose or (Fructosyl) m -Fructose where n represents an integer from 1 to 8 and m represents an integer from 1 to 8. In most cases the preparations of FOS are not homogeneous. They include mixtures of chains of variable size.
- the polymers correspond to the formula Glucosyl- (Fructosyl) n -Fructose (l ⁇ n ⁇ 8)
- the FOS prepared by hydrolysis correspond to the two formulas Glucosyl- (Fructosyl) n-Fructose and / or (Fructosyl) m -Fructose (l ⁇ n ⁇ 8 and l ⁇ m ⁇ 8).
- the FOS include in particular short-chain fructo-oligosaccharides, synthesized by transfructosylation, for which the degree of polymerization is less than 6, and in particular short chain FOS with 2, 3 or 4 fructose units such as 1-kestose, nystose and fructosyl-nystose
- Fructans are polymers in which the fructosyl-fructose type bonds are predominant.
- the galacto-oligosaccharides are formed from 2 to 6 hexose units, they mainly include galactose as the basic unit. They are synthesized by the action of ⁇ -galactosidase on lactose.
- the xylo-oligosaccharides come from the hydrolysis of xylan, they are composed of xylose. Soy oligosaccharides are extracted from soy, they are mainly mixtures of oligosaccharides comprising from 1 to 4 sugar units, the main components being raffinose ⁇ and stachyose-.
- Gentio-oligosaccharides are polymers resulting from the digestion of starch, for which the major part of the bonds is of the form ⁇ -glucopyranosyl- (1-6) -glucopyranose.
- Isomaltosaccharides are also glucose polymers resulting from the hydrolysis of starch, they are mixtures of isomaltose, panose, isomaltotriose and other branched polymers with 4 or 5 glucose units.
- the inventors have shown that the addition of prebiotics in the food ration, advantageously the addition of FOS, makes it possible to reduce the oxidative stress due in particular to a diet rich in sugars, and in particular in fructose.
- the object of the invention is to provide new means of preventing or treating oxidative stress.
- the subject of the invention is the use of prebiotics for the preparation of food preparations, ahcaments, or pharmaceutical compositions intended for the prevention or treatment of oxidative stress.
- a more particular subject of the invention is the aforementioned use of at least one oligosaccharide chosen from:
- the invention relates more particularly to the above-mentioned use of fructo-oligosaccharides (FOS) of general formula Glucosyl- (Fructosyl) n -Fructose or (Fructosyl) m - Fructose where n represents an integer from 1 to 8, in particular from 1 to 5, and m represents an integer from 1 to 8, in particular from 1 to 5, such as the short chain FOS 1-kestose, nystose or fructosyl-nystose.
- FOS fructo-oligosaccharides
- Another subject of the invention is the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of sugars.
- the invention relates more particularly to the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of fructose.
- the invention relates in particular to the use of prebiotics in the context of the prevention or treatment of oxidative stress due to consumption of food fruetose greater than about 50 g / day on average.
- the invention also relates to the use of prebiotics, for which said prebiotics are administered at a daily dose of approximately 1 g to approximately 20 g, in particular from approximately 2 g to approximately 17 g, in particular from approximately 5 g to approximately 15 g.
- the invention also relates to the use of prebiotics as compounds having an anti-free radical effect in the context of the prevention or treatment of oxidative stress.
- the invention also relates to the use of prebiotics as compounds having an anti-aging effect linked to an effect of protection of the cells of the organism against the action of free radicals.
- the invention also relates to any food preparation comprising simple carbohydrates in combination with prebiotics.
- the invention relates more particularly to a food preparation comprising: at least one simple carbohydrate such as fructose or sucrose, in combination with one or more oligosaccharides chosen from:
- the food preparation of the invention is such that the proportion of prebiotics represents by weight at least 5% of the amount of simple carbohydrates present in said preparation.
- the invention relates in particular to a food preparation for which the proportion by weight of fructo-oligosaccharides (FOS) relative to the amount of fructose present in said preparation varies between 10% and 100% and is in particular from approximately 15% to approximately 35 % and is notably around 20%.
- FOS fructo-oligosaccharides
- the invention relates in particular to a food preparation comprising a mixture of fructo-oligosaccharides (FOS), as defined above, comprising 64% of Glucosyl-
- FOS fructo-oligosaccharides
- the invention relates more particularly to a food preparation comprising a mixture of fructo-oligosaccharides (FOS), as defined above, comprising 64% of Glucosyl- (Fructosyl) n -Fructose and 36% of (Fructosyl) m -Fructose, of average polymerization degrees 4.8, the proportion by weight of said FOS present in said preparation varying between 10% o and 100%, and being in particular from approximately 15% to approximately 35%, preferably approximately 20% o, by relative to the amount of fructose present in said preparation.
- FOS fructo-oligosaccharides
- the blend of FOS used corresponds to the preparation Raftilose ® of ORAFTI P 5, Thienen, Belgium.
- the subject of the invention is also a food product containing the food preparation defined above, said food product being chosen from a group comprising pastries, confectionery, desserts, drinks, cereal bars, chocolate bars, sweet bars, breakfast cereals, dairy products and dietary supplements.
- the inventors have shown, on an animal model, that the addition of fructo-oligosaccharides (FOS) in the food ration makes it possible to reduce the oxidative stress due to a diet enriched in fructose.
- FOS fructo-oligosaccharides
- the rats were placed in wire bottom cages in a temperature-controlled room (22 ° C) with 12-hour day / night cycles. The animals were treated according to the recommendations of the Ethics Committee of INRA, decree n ° 87-848.
- the rats were first fed on a semi-purified starch-based diet for 7 days. They were then randomly divided into 4 groups of 1-0 rats: -a starch group (A), a fructose group (F), a starch group + FOS (A / FOS) and a fructose group + FOS (F / FOS ). They then followed their proper diet for 4 weeks. Food and distilled water were provided ad libitum. The composition of the food rations was as follows (in g / kg):
- Vitamin blend (AIN-76A) 10 10 10 10 10
- the mixtures AIN-76 and ALN-76A were supplied by I ⁇ N Biomedicals, Orsay,> France.
- the FOS (Raftilose ® P 95 ) were obtained from ORAFTI, Thienen, Belgium. They were gradually introduced into the diet in order to avoid diarrhea which could start in response to the too rapid administration of large quantities of this compound.
- Raftilose ® P 5 is a mixture of Glucosyl- (Fructosyl) n -Fructose (64%) and (Fructosyl) m - Fructose (36%) with an average degree of polymerization 4.8. 4 days before sacrifice, the animals were kept individually in stainless steel cages with ad libitum access to water and food.
- Urine samples were collected 24 hours before sacrifice in 50 ml graduated tubes, volumes were precisely measured, the samples were then centrifuged and stored at -80 ° C until analysis. At the time of sacrifice, the rats were weighed, then anesthetized using sodium pentobarbital (40 mg / kg intraperitoneal injection) and killed. Blood was taken from the abdominal aorta and collected in heparinized tubes. The plasma obtained after centrifugation at low speed (2000 g, 15 min) was stored at -80 ° C for biochemical analyzes. The heart was quickly removed and then washed in an ice-cold saline solution.
- TBARS thiobarbituric acid
- TBARS lipid peroxidation of a sample subjected to oxidative stress.
- the plasma TBARS levels were determined by spectrofluorometry on an LS 5 device (Perkin Elmer, Norwalk, CT, USA). A method adapted from Okhawa et al. (1979) was used as previously described (Rayssiguier et al, 1993). The level of urinary TBARS was measured as described in Lee et al. (1992) and calculated on the basis of a 24-hour urine volume. Finally, the measurement of cardiac TBARS was based on Ohkawa et al. (1979), they allow the evaluation of the susceptibility of cardiac lipids to peroxidation.
- the cardiac tissues were homogenized on ice in a ratio of 1 g of fresh tissue to 9 ml of KC1 150 mmol / 1 using a Polytron homogenizer, these homogenates were then subjected to a lipid peroxidation induced by a FeSO 4 mixture (2 ⁇ mol 1) - ascorbate (50 ⁇ mol / 1) for 30 min in a bath at 37 ° C. in the absence of oxygen, a control 1,1,3,3-tetraethoxypropane was used; TBARS were then measured by spectrophotometry (Uvikon 941 plus series, Kontron Instruments, St Quentin en Yvelines, France).
- TBARS u ⁇ natres 11 99 ⁇ 0.50 21.97 ⁇ 1.58 13.40 ⁇ 0.53 15.86 ⁇ 1.19 ⁇ 0.001 ⁇ 0.05 ⁇ 0.001 nmol / 24h. ,, -. - -. ,. . i * - -, -
- results are the averages for 10 animals ⁇ standard deviation a p value for ANOVA The ANOVA results are significant for p ⁇ 0.05, NS not significant
- the TBARS of the Fructose + FOS group are significantly lower than those of the Fructose group and are not significantly different from those of the Amidon + FOS group. FOS therefore make it possible to limit oxidative stress due to the consumption of fructose.
- Vitamin E / plasma triglyceride ratio allows is a reflection of the oxidative stress to which an organism has been subjected. The lower the value of this ratio, the higher the level of oxidative stress.
- Plasma triglyceride concentrations were measured using enzymatic procedures according to the supplier's recommendations (Biotrol, Paris, France).
- a multipurpose control serum (Biotrol-33-plus) was treated in parallel with the samples in order to check the accuracy of the results of the plasma analysis.
- Plasma vitamin E concentrations were determined by reverse-phase high performance liquid chromatography on a Kontron series 400 device (Kontron St Quentin en Yvelines, France) using a hexane extract. ⁇ -Tocopherol acetate (Sigma) was added to the samples as an internal control. The samples were extracted twice with hexane after precipitation of the proteins with ethanol.
- the extract was dried under nitrogen, dissolved in an ethanol-methylene chloride mixture (65:35, v / v) and injected onto a C 18 column (nucleosil; 250 mm in length, di 46 mm., Particles of 5 .mu.m). Pure methanol made it possible to elute the ⁇ -tocopherol in 5 min and the tocopherol acetate in 6.3 min at a flow rate of 2 ml / min. The compounds were detected by UV (292 nm) and then quantified by internal and external calibrations using control solutions.
- Vitamin E 9.01 ⁇ 0.54 9.74 ⁇ 0.92 7.21 ⁇ 0.35 8.74 ⁇ 0.62 NS ⁇ 0.05 NS ⁇ g / ml
- results are the means calculated for 10 animals ⁇ standard deviation. has value of p for ANOVA. ANOVA results are significant for p ⁇ 0.05, NS, not significant
- the high fructose diet decreases the ratio
- Vitamin E / TG which testifies to the existence of oxidative stress.
- FOS supplementation prevents the reduction of this ratio, in other words decreases the oxidative stress resulting from the consumption of the diet rich in fructose.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention concerns the use of prebiotics for preparing food preparations, functional foods, or pharmaceutical compositions for preventing or treating oxidation stress related in particular to fructose consumption. The invention also concerns a food preparation comprising simple carbohydrates, in particular fructose, associated with prebiotics.
Description
UTILISATION DE PREBIOTIQUES POUR PREVENIR OU TRAITER LE STRESS USE OF PREBIOTICS TO PREVENT OR TREAT STRESS
OXYDANTOXYDANT
La présente invention a pour objet l'utilisation de prébiotiques pour la préparation de préparations alimentaires, d'ahcaments, ou de compositions pharmaceutiques destinés à la prévention ou au traitement du stress oxydant.The present invention relates to the use of prebiotics for the preparation of food preparations, ahcaments, or pharmaceutical compositions intended for the prevention or treatment of oxidative stress.
Le stress oxydant est le résultat d'un déséquilibre au sein de l'organisme en faveur des espèces pro-oxydantes par rapport aux espèces anti-oxydantes.Oxidative stress is the result of an imbalance within the body in favor of pro-oxidant species compared to antioxidant species.
Les espèces pro-oxydantes sont d'une manière générale des radicaux libres et notamment des radicaux libres oxygénés. La présence d'un électron non apparié rend ces composés extrêmement réactifs vis-à-vis des macromolécules biologiques de l'organisme ; les lipides, les glucides, les protéines et les acides nucléiques sont ainsi des cibles privilégiées de" ces espèces. La dégradation oxydative de ces macromolécules entraîne de nombreux dysfonctionnements cellulaires. L'origine de ces radicaux libres prend essentiellement sa source dans le métabolisme de l'oxygène. La plus grande partie du stress oxydant provient du métabolisme énergétique. L'étape finale de l'oxydation des aliments, à savoir la chaîne respiratoire mitochondriale, est ainsi à l'origine de la formation de radicaux libres oxygénés. De plus, au cours de la réaction inflammatoire, la stimulation des cellules phagocytaires s'accompagne également de la formation de radicaux libres.The pro-oxidant species are generally free radicals and in particular oxygenated free radicals. The presence of an unpaired electron makes these compounds extremely reactive towards the biological macromolecules of the organism; lipids, carbohydrates, proteins and nucleic acids are thus privileged targets of "these species. The oxidative degradation of these macromolecules leads to numerous cellular dysfunctions. The origin of these free radicals essentially takes its source in the metabolism of Most of the oxidative stress comes from energy metabolism, so the final stage of food oxidation, the mitochondrial respiratory chain, is responsible for the formation of oxygenated free radicals. during the inflammatory reaction, stimulation of phagocytic cells is also accompanied by the formation of free radicals.
Les défenses anti-oxydantes de l'organisme font appel à des systèmes protéiques, tels que la superoxyde dismutase, mais également à des composés anti-oxydants apportés par l'alimentation, tels que les vitamines C et E, ou d'autres nutriments, comme les caroténoïdes, les polyphénols ou les flavonoïdes. Des déséquilibres alimentaires peuvent être à l'origine du stress oxydant. LesThe body's antioxidant defenses call on protein systems, such as superoxide dismutase, but also on antioxidant compounds provided by food, such as vitamins C and E, or other nutrients, like carotenoids, polyphenols or flavonoids. Dietary imbalances can be the cause of oxidative stress. The
Inventeurs ont en particulier montré précédemment qu'une alimentation trop riche en sucres, et notamment en saccharose (Busserolles et al, 2002a) et en fructose (Busserolles et al, 2002b), pouvait générer un stress oxydant important. Ces effets pro-oxydants sont d'autant plus importants que l'alimentation est appauvrie en antioxydants. Le fructose est un monosaccharide dont la consommation a fortement augmenté, soit en tant que tel soit sous forme de saccharose. Du fait de leur faible coût d'obtention, les sirops riches en fructose issus du maïs sont préférentiellement utilisés dans les boissons sucrées. Alors que le fructose est naturellement présent dans le miel et dans les fruits où il est associé à de nombreux micronutriments protecteurs, on peut s'interroger sur les conséquences pour la
santé, d'une augmentation sans limite de ce glucide sous forme purifiée. En effet, le fructose possède de nombreuses propriétés qui le distinguent des autres sucres et l'apport élevé de ce glucide pourrait être responsable d'effets métaboliques indésirables.The inventors have in particular shown previously that a diet too rich in sugars, and in particular in sucrose (Busserolles et al, 2002a) and in fructose (Busserolles et al, 2002b), could generate significant oxidative stress. These pro-oxidant effects are all the more important as the diet is depleted in antioxidants. Fructose is a monosaccharide whose consumption has greatly increased, either as such or in the form of sucrose. Due to their low cost of obtaining, syrups rich in fructose from corn are preferably used in sugary drinks. While fructose is naturally present in honey and in fruits where it is associated with many protective micronutrients, one can wonder about the consequences for health, an unlimited increase in this purified carbohydrate. Indeed, fructose has many properties that distinguish it from other sugars and the high intake of this carbohydrate could be responsible for undesirable metabolic effects.
Les modalités de lutte contre le stress oxydant passent d'une manière générale par l'utilisation de nutriments anti-radicalaires ayant un effet direct sur les radicaux libres : les carotènes, l'acide ascorbique (vitamine C), les tocophérols (vitamine E), les polyphénols (brevet US n°6 207 702).The methods of combating oxidative stress generally involve the use of anti-free radical nutrients having a direct effect on free radicals: carotenes, ascorbic acid (vitamin C), tocopherols (vitamin E) , polyphenols (US Patent No. 6,207,702).
La présente invention découle de la mise en évidence par les Inventeurs du fait que les prébiotiques et plus particulièrement les fructo-oligosaccharides (FOS) permettent de lutter contre le stress oxydant résultant d'un excès de fructose dans l'alimentation.The present invention stems from the discovery by the inventors of the fact that prebiotics and more particularly fructo-oligosaccharides (FOS) make it possible to combat oxidative stress resulting from an excess of fructose in the diet.
Les prébiotiques sont des glucides complexes non-digestibles dégradées par les micro- organismes,, de. la flore intestinale, et dont la dégradation- est responsable d'effets bénéfiques < pour la santé de l'hôte. Ces micro -organismes sont en règle générale des bactéries, et notamment des bifodobactéries, que l'on retrouve essentiellement dans le colon. Les effets bénéfiques provoqués par lesdits micro-organismes peuvent être dus à la stimulation sélective de la croissance de certaines espèces de micro-organismes, notamment les bifodobactéries, et/ou à la libération de métabolites issus de la transformation des prébiotiques par les microorganismes.Prebiotics are complex, non-digestible carbohydrates degraded by microorganisms. the intestinal flora, and whose degradation- is responsible for beneficial effects <for the health of the host. These microorganisms are generally bacteria, and in particular bifodobacteria, which are found mainly in the colon. The beneficial effects caused by said microorganisms may be due to the selective stimulation of the growth of certain species of microorganisms, in particular bifodobacteria, and / or to the release of metabolites resulting from the transformation of prebiotics by microorganisms.
En l'état actuel, les seuls pré-biotiques clairement définis sont des polymères de sucres de degré de polymérisation compris entre 2 et 12, classés parmi les glucides complexes : les oligosaccharides. On peut ainsi citer, outre les fructo-oligosaccharides dont les effets sont les plus documentés, les fructanes, les galacto-oligosaccharides, les xylo-oligosaccharides, les oligosaccharides de soja, les gentio-oligosaccharides ou encore les isomalto-oligosaccharides.As it stands, the only clearly defined pre-biotics are sugar polymers with a degree of polymerization between 2 and 12, classified among complex carbohydrates: oligosaccharides. Mention may thus be made, in addition to the fructo-oligosaccharides whose effects are the most documented, fructans, galacto-oligosaccharides, xylo-oligosaccharides, soy oligosaccharides, gentio-oligosaccharides or isomalto-oligosaccharides.
Les fructo-oligosaccharides (FOS) sont obtenus soit par hydrolyse de l'inuline, soit par synthèse enzymatique, par transfructosylation à partir de précurseurs saccharidiques. Ils répondent à la formule générale Glucosyl-(Fructosyl)n-Fructose ou (Fructosyl)m-Fructose où n représente un nombre entier de 1 à 8 et m représente un nombre entier de 1 à 8. Dans la plupart des cas les préparations de FOS ne sont pas homogènes. Elles comportent des mélanges de chaînes de taille variable. Par ailleurs, dans le cas de la préparation des FOS par synthèse enzymatique, les polymères répondent à la formule Glucosyl-(Fructosyl)n-Fructose (l<n<8), tandis que les FOS préparés par hydrolyse répondent aux deux formules Glucosyl- (Fructosyl)n-Fructose et/ou (Fructosyl)m-Fructose (l≤n<8 et l≤m<8). Les FOS comprennent en particulier les fructo-oligosaccharides à chaîne courte, synthétisés par transfructosylation,
pour lesquels le degré de polymérisation est inférieur à 6, et notamment des FOS à chaîne courte à 2, 3 ou 4 unités fructoses tels que le 1-kestose, le nystose et le fructosyl-nystoseFructo-oligosaccharides (FOS) are obtained either by hydrolysis of inulin, or by enzymatic synthesis, by transfructosylation from saccharide precursors. They correspond to the general formula Glucosyl- (Fructosyl) n -Fructose or (Fructosyl) m -Fructose where n represents an integer from 1 to 8 and m represents an integer from 1 to 8. In most cases the preparations of FOS are not homogeneous. They include mixtures of chains of variable size. Furthermore, in the case of the preparation of FOS by enzymatic synthesis, the polymers correspond to the formula Glucosyl- (Fructosyl) n -Fructose (l <n <8), while the FOS prepared by hydrolysis correspond to the two formulas Glucosyl- (Fructosyl) n-Fructose and / or (Fructosyl) m -Fructose (l≤n <8 and l≤m <8). The FOS include in particular short-chain fructo-oligosaccharides, synthesized by transfructosylation, for which the degree of polymerization is less than 6, and in particular short chain FOS with 2, 3 or 4 fructose units such as 1-kestose, nystose and fructosyl-nystose
Les fructanes sont des polymères dans lesquels les liaisons de type fructosyl-fructose sont majoritaires. Les galacto-oligosaccharides sont formés de 2 à 6 unités hexoses, ils comprennent principalement le galactose comme unité de base. Ils sont synthétisés par l'action de la β- galactosidase sur le lactose.Fructans are polymers in which the fructosyl-fructose type bonds are predominant. The galacto-oligosaccharides are formed from 2 to 6 hexose units, they mainly include galactose as the basic unit. They are synthesized by the action of β-galactosidase on lactose.
Les xylo-oligosaccharides sont issus de l'hydrolyse du xylane, ils sont composés de xylose. Les oligosaccharides de soja sont extraits du soja, il s'agit principalement de mélanges d'oligosaccharides comprenant de 1 à 4 unités osidiques, les principaux composants étant le raffinose < et le stachyose-.The xylo-oligosaccharides come from the hydrolysis of xylan, they are composed of xylose. Soy oligosaccharides are extracted from soy, they are mainly mixtures of oligosaccharides comprising from 1 to 4 sugar units, the main components being raffinose <and stachyose-.
Les gentio-oligosaccharides sont des polymères issus de la digestion de l'amidon, pour lesquels la majeure partie des liaison est de la forme β-glucopyranosyl-(l-»6)-glucopyranose. Les isomalto-saccharides sont également des polymères de glucose issus de l'hydrolyse de l'amidon, il s'agit de mélanges d'isomaltose, de panose, d'isomaltotriose et d'autres polymères branchés comptant 4 ou 5 unités glucoses.Gentio-oligosaccharides are polymers resulting from the digestion of starch, for which the major part of the bonds is of the form β-glucopyranosyl- (1-6) -glucopyranose. Isomaltosaccharides are also glucose polymers resulting from the hydrolysis of starch, they are mixtures of isomaltose, panose, isomaltotriose and other branched polymers with 4 or 5 glucose units.
Les Inventeurs ont montré que l'ajout de prébiotiques dans la ration alimentaire, avantageusement l'ajout de FOS, permettait de diminuer le stress oxydant dû en particulier à un régime alimentaire riche en sucres, et notamment en fructose.The inventors have shown that the addition of prebiotics in the food ration, advantageously the addition of FOS, makes it possible to reduce the oxidative stress due in particular to a diet rich in sugars, and in particular in fructose.
L'invention a pour but de fournir de nouveaux moyens de prévenir ou de traiter le stress oxydant.The object of the invention is to provide new means of preventing or treating oxidative stress.
L'invention a pour objet l'utilisation de prébiotiques pour la préparation de préparations alimentaires, d'ahcaments, ou de compositions pharmaceutiques destinés à la prévention ou au traitement du stress oxydant.The subject of the invention is the use of prebiotics for the preparation of food preparations, ahcaments, or pharmaceutical compositions intended for the prevention or treatment of oxidative stress.
L'invention a plus particulièrement pour objet l'utilisation susmentionnée d'au moins un oligosaccharide choisis parmi :A more particular subject of the invention is the aforementioned use of at least one oligosaccharide chosen from:
- les fructanes- fructans
- les fructo-oligosaccharides (FOS) - les galacto-oligosaccharides- fructo-oligosaccharides (FOS) - galacto-oligosaccharides
- les xylo-oligosaccharides- xylo-oligosaccharides
- les oligosaccharides de soja- soy oligosaccharides
- les gentio-oligosaccharides- gentio-oligosaccharides
- les isomalto-oligosaccharides
tels que définis ci-dessus.- isomalto-oligosaccharides as defined above.
L'invention concerne plus particulièrement l'utilisation susmentionnée de fructo- oligosaccharides (FOS) de formule générale Glucosyl-(Fructosyl)n-Fructose ou (Fructosyl)m- Fructose où n représente un nombre entier de 1 à 8, notamment de 1 à 5, et m représente un nombre entier de 1 à 8, notamment de 1 à 5, tels que les FOS à chaîne courte 1-kestose, nystose ou fructosyl-nystose.The invention relates more particularly to the above-mentioned use of fructo-oligosaccharides (FOS) of general formula Glucosyl- (Fructosyl) n -Fructose or (Fructosyl) m - Fructose where n represents an integer from 1 to 8, in particular from 1 to 5, and m represents an integer from 1 to 8, in particular from 1 to 5, such as the short chain FOS 1-kestose, nystose or fructosyl-nystose.
L'invention a également pour objet l'utilisation de prébiotiques dans le cadre de la prévention ou du traitement du stress oxydant lié à la consommation de sucres.Another subject of the invention is the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of sugars.
L'invention concerne plus particulièrement l'utilisation de prébiotiques dans le cadre de la prévention ou du traitement du stress oxydant lié à la consommation de fructose.The invention relates more particularly to the use of prebiotics in the context of the prevention or treatment of oxidative stress linked to the consumption of fructose.
L'invention concerne notamment l'utilisation de prébiotiques dans le cadre de la prévention ou du traitement du stress oxydant dû à une consommation de fruetose'alimentaire supérieure à environ 50 g/jour en moyenne.The invention relates in particular to the use of prebiotics in the context of the prevention or treatment of oxidative stress due to consumption of food fruetose greater than about 50 g / day on average.
L'invention concerne également l'utilisation de prébiotiques, pour laquelle lesdits prébiotiques sont administrés à une dose journalière d'environ 1 g à environ 20 g, notamment d'environ 2 g à environ 17 g, notamment d'environ 5 g à environ 15 g.The invention also relates to the use of prebiotics, for which said prebiotics are administered at a daily dose of approximately 1 g to approximately 20 g, in particular from approximately 2 g to approximately 17 g, in particular from approximately 5 g to approximately 15 g.
L'invention a également pour objet l'utilisation de prébiotiques en tant que composés ayant un effet antiradicalaire dans le cadre de la prévention ou du traitement du stress oxydant. L'invention a également pour objet l'utilisation de prébiotiques en tant que composés ayant un effet anti-vieillissement lié à un effet de protection des cellules de l'organisme contre l'action des radicaux libres.The invention also relates to the use of prebiotics as compounds having an anti-free radical effect in the context of the prevention or treatment of oxidative stress. The invention also relates to the use of prebiotics as compounds having an anti-aging effect linked to an effect of protection of the cells of the organism against the action of free radicals.
L'invention concerne également toute préparation alimentaire comprenant des glucides simples en association avec des prébiotiques. L'invention concerne plus particulièrement une préparation alimentaire comprenant : au moins un glucide simple tel que le fructose ou le saccharose, en association avec un ou plusieurs oligosaccharides choisis parmi :The invention also relates to any food preparation comprising simple carbohydrates in combination with prebiotics. The invention relates more particularly to a food preparation comprising: at least one simple carbohydrate such as fructose or sucrose, in combination with one or more oligosaccharides chosen from:
- les fructanes- fructans
- les fructo-oligosaccharides (FOS) - les galacto-oligosaccharides- fructo-oligosaccharides (FOS) - galacto-oligosaccharides
- les xylo-oligosaccharides- xylo-oligosaccharides
- les oligosaccharides de soja- soy oligosaccharides
- les gentio-oligosaccharides- gentio-oligosaccharides
- les isomalto-oligosaccharides
tels que définis ci-dessus. Avantageusement la préparation alimentaire de l'invention est telle que la proportion en prébiotiques représente en poids au moins 5% de la quantité de glucides simples présents dans ladite préparation. L'invention concerne notamment une préparation alimentaire pour laquelle la proportion en poids de fructo-oligosaccharides (FOS) par rapport à la quantité de fructose présent dans ladite préparation varie entre 10% et 100% et est notamment d'environ 15% à environ 35% et est notamment d'environ 20%.- isomalto-oligosaccharides as defined above. Advantageously, the food preparation of the invention is such that the proportion of prebiotics represents by weight at least 5% of the amount of simple carbohydrates present in said preparation. The invention relates in particular to a food preparation for which the proportion by weight of fructo-oligosaccharides (FOS) relative to the amount of fructose present in said preparation varies between 10% and 100% and is in particular from approximately 15% to approximately 35 % and is notably around 20%.
L'invention concerne notamment une préparation alimentaire comprenant un mélange de fructo-oligosaccharides (FOS), tels que définis ci-dessus, comprenant 64% de Glucosyl-The invention relates in particular to a food preparation comprising a mixture of fructo-oligosaccharides (FOS), as defined above, comprising 64% of Glucosyl-
(Fructosyl)n -Fructose et 36% de (Fructosyl)m-Fructose de degrés de polymérisation moyens(Fructosyl) n -Fructose and 36% of (Fructosyl) m -Fructose of average degrees of polymerization
• 4,8. • 4.8.
L'invention concerne plus particulièrement une préparation alimentaire comprenant un mélange de fructo-oligosaccharides (FOS), tels que définis ci-dessus, comprenant 64% de Glucosyl-(Fructosyl)n-Fructose et 36% de (Fructosyl)m-Fructose, de degrés de polymérisation moyens 4,8, la proportion en poids desdits FOS présents dans ladite préparation variant entre 10%o et 100%, et étant notamment d'environ 15% à environ 35%, préférablement d'environ 20%o, par rapport à la quantité de fructose présent dans ladite préparation.The invention relates more particularly to a food preparation comprising a mixture of fructo-oligosaccharides (FOS), as defined above, comprising 64% of Glucosyl- (Fructosyl) n -Fructose and 36% of (Fructosyl) m -Fructose, of average polymerization degrees 4.8, the proportion by weight of said FOS present in said preparation varying between 10% o and 100%, and being in particular from approximately 15% to approximately 35%, preferably approximately 20% o, by relative to the amount of fructose present in said preparation.
Selon un mode de réalisation préféré, le mélange de FOS utilisé correspond à la préparation Raftilose® P 5 d'ORAFTI, Thienen, Belgique.According to a preferred embodiment, the blend of FOS used corresponds to the preparation Raftilose ® of ORAFTI P 5, Thienen, Belgium.
L'invention a également pour objet un produit alimentaire contenant la préparation alimentaire définie ci-dessus, ledit produit alimentaire étant choisi parmi un groupe comprenant les pâtisseries, les confiseries, les desserts, les boissons, les barres aux céréales, les barres chocolatées, les barres sucrées, les céréales de petit déjeuner, les produits laitiers et les compléments alimentaires.
The subject of the invention is also a food product containing the food preparation defined above, said food product being chosen from a group comprising pastries, confectionery, desserts, drinks, cereal bars, chocolate bars, sweet bars, breakfast cereals, dairy products and dietary supplements.
Description de l'inventionDescription of the invention
Les Inventeurs ont montré, sur un modèle animal, que l'ajout de fructo- oligosaccharides (FOS) dans la ration alimentaire permettait de réduire le stress oxydant dû à une alimentation enrichie en fructose.The inventors have shown, on an animal model, that the addition of fructo-oligosaccharides (FOS) in the food ration makes it possible to reduce the oxidative stress due to a diet enriched in fructose.
40 rats maies sevrés de type Wistar-Han (IFF A-CREDO ; L'Arbresle, France) âgés de40 weaned Wistar-Han type rats (IFF A-CREDO; L'Arbresle, France) aged
6 semaines et pesant environ 150 g ont été utilisés. Les rats ont été placés dans des cages à fond grillagé dans une pièce à température contrôlée (22°C) avec des cycles jour/nuit de 12 heures. Les animaux ont été traités selon les recommandations du Comité Ethique de l'INRA, décret n°87-848.6 weeks and weighing approximately 150 g were used. The rats were placed in wire bottom cages in a temperature-controlled room (22 ° C) with 12-hour day / night cycles. The animals were treated according to the recommendations of the Ethics Committee of INRA, decree n ° 87-848.
Les rats ont tout d'abord été nourris suivant un régime semi-purifié à base d'amidon pendant 7 jours. Ils ont ensuite été divisés aléatoirement en 4 groupes de 1-0 rats :-un groupe amidon (A), un groupe fructose (F), un groupe amidon + FOS (A/FOS) et un groupe fructose + FOS (F/FOS). Ils ont alors suivi leur régime alimentaire approprié durant 4 semaines. La nourriture et l'eau distillée ont été fournies ad libitum. La composition des rations alimentaires était comme suit (en g/kg) :The rats were first fed on a semi-purified starch-based diet for 7 days. They were then randomly divided into 4 groups of 1-0 rats: -a starch group (A), a fructose group (F), a starch group + FOS (A / FOS) and a fructose group + FOS (F / FOS ). They then followed their proper diet for 4 weeks. Food and distilled water were provided ad libitum. The composition of the food rations was as follows (in g / kg):
Groupe A Groupe F Groupe A/FOS Groupe F/FOSGroup A Group F Group A / FOS Group F / FOS
Amidon 650 - 550 -Starch 650 - 550 -
Fructose - 650 - 550Fructose - 650 - 550
FOS (Raftilose® P95) - - 100 100FOS (Raftilose® P 95 ) - - 100 100
Caséine 200 200 200 200Casein 200 200 200 200
Huile de maïs 50 50 50 50Corn oil 50 50 50 50
Alphacel 50 50 50 50Alphacel 50 50 50 50
Méthionine D,L 3 3 3 3Methionine D, L 3 3 3 3
Bitartrate de chohne 2 2 2 2Chohne bitartrate 2 2 2 2
Mélange de minéraux (AIN-76) 35 35 35 35Mixture of minerals (AIN-76) 35 35 35 35
Mélange de vitamines (AIN-76A) 10 10 10 10Vitamin blend (AIN-76A) 10 10 10 10
Les mélanges AIN-76 et ALN-76A ont été fournis par IÇN Biomedicals, Orsay, > France. Les FOS (Raftilose® P95) ont été obtenus auprès d'ORAFTI, Thienen, Belgique. Ils ont été introduits dans l'alimentation progressivement afin d'éviter des diarrhées pouvant se déclencher en réponse à l'administration trop rapide de quantités importantes de ce composé. Le Raftilose® P 5 est un mélange de Glucosyl-(Fructosyl)n-Fructose (64%) et de (Fructosyl)m- Fructose (36%) de degrés de polymérisation moyen 4,8. 4 jours avant sacrifice, les animaux ont été maintenus individuellement dans des cages en acier inoxydable avec accès ad libitum à l'eau et à la nourriture. Des échantillons d'urine ont été récupérés 24 heures avant le sacrifice dans des tubes gradués de 50 ml, les volumes
ont été mesurés précisément, les échantillons ont alors été centrifugés et conservés à -80°C jusqu'à l'analyse. Au moment du sacrifice les rats ont été pesés, puis anesthésiés à l'aide de pentobarbital de sodium (injection intra-péritonéale de 40 mg/kg) et tués. Le sang a été prélevé à partir de l'aorte abdominale et récupéré dans des tubes héparinés. Le plasma obtenu après centrifugation à basse vitesse (2000 g, 15 min) a été conservé à -80°C pour les analyses biochimiques. Le cœur a été prélevé rapidement puis lavé dans une solution saline glacéeThe mixtures AIN-76 and ALN-76A were supplied by IÇN Biomedicals, Orsay,> France. The FOS (Raftilose ® P 95 ) were obtained from ORAFTI, Thienen, Belgium. They were gradually introduced into the diet in order to avoid diarrhea which could start in response to the too rapid administration of large quantities of this compound. Raftilose ® P 5 is a mixture of Glucosyl- (Fructosyl) n -Fructose (64%) and (Fructosyl) m - Fructose (36%) with an average degree of polymerization 4.8. 4 days before sacrifice, the animals were kept individually in stainless steel cages with ad libitum access to water and food. Urine samples were collected 24 hours before sacrifice in 50 ml graduated tubes, volumes were precisely measured, the samples were then centrifuged and stored at -80 ° C until analysis. At the time of sacrifice, the rats were weighed, then anesthetized using sodium pentobarbital (40 mg / kg intraperitoneal injection) and killed. Blood was taken from the abdominal aorta and collected in heparinized tubes. The plasma obtained after centrifugation at low speed (2000 g, 15 min) was stored at -80 ° C for biochemical analyzes. The heart was quickly removed and then washed in an ice-cold saline solution.
(NaCl 9 g/1), placé dans de l'azote liquide et conservé à -80°C.(NaCl 9 g / 1), placed in liquid nitrogen and stored at -80 ° C.
Deux types de mesures bien connues de l'homme de l'art ont alors été réalisées afin de déterminer l'intensité du stress oxydant des animaux en fonction de leur régime alimentaire : une mesure des substances réactives à l'acide thiobarbiturique (TBARS) et une mesure du rapport des concentrations plasmatiques en vitamine E et en triglycérides.Two types of measurement well known to those skilled in the art were then carried out in order to determine the intensity of the oxidative stress of the animals as a function of their diet: a measurement of the reactive substances with thiobarbituric acid (TBARS) and a measurement of the ratio of plasma concentrations of vitamin E and triglycerides.
Une. analyse, statistique, des, résultats- a .été réalisée à l'aide- du programme^ Statview--A. analysis, statistics, of, results- was. carried out using- the program ^ Statview--
(Abacus Concenpts Inc., Berkeley, CA). Les données ont été exprimées comme la moyenne des résultats obtenus pour les 10 animaux de chaque groupe alimentaire ± écart-type. L'analyse de la variance (ANOVA ; P<0,05) a été utilisée afin de déterminer les principaux effets (sucre et FOS) et leurs interactions. Les différences ont été considérées significatives lorsque p<0,05.(Abacus Concenpts Inc., Berkeley, CA). Data were expressed as the average of the results obtained for the 10 animals in each food group ± standard deviation. Analysis of variance (ANOVA; P <0.05) was used to determine the main effects (sugar and FOS) and their interactions. The differences were considered significant when p <0.05.
Ces résultats indiquent que les animaux suivant le régime fructose sont soumis à un stress oxydant significativement supérieur à celui des animaux témoins (soumis au régime amidon) et que l'ajout de FOS permet de réduire significativement le stress oxydant lié à la consommation de fructose.These results indicate that animals following the fructose diet are subjected to oxidative stress significantly greater than that of control animals (subjected to the starch diet) and that the addition of FOS makes it possible to significantly reduce the oxidative stress linked to the consumption of fructose.
Exemple 1 j Mesure des substances réactives à l'acide thiobarbiturique (TBARS)Example 1 j Measurement of Thiobarbituric Acid Reactive Substances (TBARS)
La mesure des TBARS permet d'évaluer le niveau de péroxydation lipidique d'un échantillon soumis à un stress oxydant. Plus la valeur des TBARS est importante plus le niveau du stress oxydant est élevé.The measurement of TBARS makes it possible to evaluate the level of lipid peroxidation of a sample subjected to oxidative stress. The higher the value of TBARS, the higher the level of oxidative stress.
Les niveaux de TBARS plasmatiques ont été déterminés par spectrofluorométrie sur un appareil LS 5 (Perkin Elmer, Norwalk, CT, USA). Une méthode adaptée d'Okhawa et al. (1979) a été utilisée comme précédemment décrit (Rayssiguier et al, 1993). Le niveau des TBARS urinaires a été mesuré comme décrit dans Lee et al. (1992) et calculé sur la base d'un volume urinaire de 24 heures. Enfin, la mesure des TBARS cardiaques s'est basée sur Ohkawa et al. (1979), ils permettent l'évaluation de la susceptibilité des lipides cardiaques à
la péroxydation. Les tissus cardiaques ont été homogénéisés sur la glace dans un rapport de 1 g de tissus frais pour 9 ml de KC1 150 mmol/1 à l'aide d'un homogéniseur Polytron, ces homogénats ont ensuite été soumis à une péroxydation lipidique induite par un mélange FeSO4 (2 μmol 1) - ascorbate (50 μmol/1) pendant 30 min dans un bain à 37°C en absence d'oxygène, un témoin 1,1,3,3-tétraéthoxypropane a été utilisé ; les TBARS ont alors été mesurées par spectrophotométrie (Uvikon 941 plus séries, Kontron Instruments, St Quentin en Yvelines, France).The plasma TBARS levels were determined by spectrofluorometry on an LS 5 device (Perkin Elmer, Norwalk, CT, USA). A method adapted from Okhawa et al. (1979) was used as previously described (Rayssiguier et al, 1993). The level of urinary TBARS was measured as described in Lee et al. (1992) and calculated on the basis of a 24-hour urine volume. Finally, the measurement of cardiac TBARS was based on Ohkawa et al. (1979), they allow the evaluation of the susceptibility of cardiac lipids to peroxidation. The cardiac tissues were homogenized on ice in a ratio of 1 g of fresh tissue to 9 ml of KC1 150 mmol / 1 using a Polytron homogenizer, these homogenates were then subjected to a lipid peroxidation induced by a FeSO 4 mixture (2 μmol 1) - ascorbate (50 μmol / 1) for 30 min in a bath at 37 ° C. in the absence of oxygen, a control 1,1,3,3-tetraethoxypropane was used; TBARS were then measured by spectrophotometry (Uvikon 941 plus series, Kontron Instruments, St Quentin en Yvelines, France).
Les résultats obtenus sont présentés dans le tableau suivant :The results obtained are presented in the following table:
Régime alimentaire Anova"Anova diet "
Amidon Fructose Amidon + FOS Fructose + FOS Sucre FOS Sucre x FOSStarch Fructose Starch + FOS Fructose + FOS Sugar FOS Sugar x FOS
TBARS plasmatiques 1,94 ± 0,03 2,14 ± 0,07 1 ,84 ± 0,02 1,96 ± 0,04 <0,01 <0,01 NS nmol/tnlPlasma TBARS 1.94 ± 0.03 2.14 ± 0.07 1.84 ± 0.02 1.96 ± 0.04 <0.01 <0.01 NS nmol / tnl
TBARS uπnatres 11 ,99 ± 0,50 21,97 ± 1,58 13,40 ± 0,53 15,86 ± 1,19 <0,001 <0,05 <0,001 nmol/24h . , , -. - -. , . . i * - - , -TBARS uπnatres 11, 99 ± 0.50 21.97 ± 1.58 13.40 ± 0.53 15.86 ± 1.19 <0.001 <0.05 <0.001 nmol / 24h. ,, -. - -. ,. . i * - -, -
TBARS cardiaques 64,9 ± 4,1 98,8 ± 6,5 73,1 ± 3,5 83,5 ± 4,7 <0,001 NS <0,05 nmol/g de poids fraisCardiac TBARS 64.9 ± 4.1 98.8 ± 6.5 73.1 ± 3.5 83.5 ± 4.7 <0.001 NS <0.05 nmol / g fresh weight
Les résultats sont les moyennes calculées pour 10 animaux ± écart-type a valeur de p pour l'ANOVA Les résultats de l'ANOVA sont significatifs pour p < 0,05, NS, non significatifsThe results are the averages for 10 animals ± standard deviation a p value for ANOVA The ANOVA results are significant for p <0.05, NS not significant
Les résultats indiquent que les TBARS plasmatiques, urinaires et cardiaques sont significativement plus élevées pour le groupe Fructose que pour le groupe Amidon. La consommation de fructose est donc responsable d'un stress oxydant plus important que celui dû à la consommation d' amidon.The results indicate that the plasma, urinary and cardiac TBARS are significantly higher for the Fructose group than for the Starch group. The consumption of fructose is therefore responsible for a greater oxidative stress than that due to the consumption of starch.
Par ailleurs, les TBARS du groupe Fructose + FOS sont significativement plus faibles que celles du groupe Fructose et ne sont pas significativement différentes de celles du groupe Amidon + FOS. Les FOS permettent donc de limiter le stress oxydant dû à la consommation de fructose.Furthermore, the TBARS of the Fructose + FOS group are significantly lower than those of the Fructose group and are not significantly different from those of the Amidon + FOS group. FOS therefore make it possible to limit oxidative stress due to the consumption of fructose.
Exemple 2Example 2
Mesure du rapport plasmatique entre la vitamine E et les triglycérides Le rapport vitamine E/triglycérides plasmatiques permet est un reflet du stress oxydant auquel a été soumis un organisme. Plus la valeur de ce rapport est faible plus le niveau du stress oxydant est important.Measurement of the plasma ratio between vitamin E and triglycerides The vitamin E / plasma triglyceride ratio allows is a reflection of the oxidative stress to which an organism has been subjected. The lower the value of this ratio, the higher the level of oxidative stress.
La mesure des concentrations de triglycérides plasmatiques a été réalisée à l'aide de procédures enzymatiques selon les recommandations du fournisseur (Biotrol, Paris, France). Un sérum témoin polyvalent (Biotrol-33-plus) a été traité en parallèle des échantillons afin de contrôler la précision des résultats de l'analyse plasmatique.
Les concentrations plasmatiques en vitamine E ont été déterminées par chromatographie liquide haute performance en phase inversée sur un appareil Kontron séries 400 (Kontron St Quentin en Yvelines, France) à l'aide d'un extrait à l'hexane. De l'acétate d'α-tocophérol (Sigma) a été ajouté aux échantillons comme témoins interne. Les échantillons ont été extraits deux fois à l'hexane après précipitation des protéines à l'éthanol. L'extrait a été séché sous azote, dissous dans un mélange éthanol-chlorure de méthylène (65 : 35, v/v) et injecté sur une colonne C18 (nucleosil ; 250 mm de longueur, d.i. 46 mm., particules de 5 μm). Le méthanol pur a permis d'éluer l'α-tocophérol en 5 min et l'acétate de tocophérol en 6,3 min à un débit de 2 ml/min. Les composés ont été détectés par UV (292 nm) puis quantifiés par des calibrages internes et externes à l'aide de solutions témoins.The plasma triglyceride concentrations were measured using enzymatic procedures according to the supplier's recommendations (Biotrol, Paris, France). A multipurpose control serum (Biotrol-33-plus) was treated in parallel with the samples in order to check the accuracy of the results of the plasma analysis. Plasma vitamin E concentrations were determined by reverse-phase high performance liquid chromatography on a Kontron series 400 device (Kontron St Quentin en Yvelines, France) using a hexane extract. Α-Tocopherol acetate (Sigma) was added to the samples as an internal control. The samples were extracted twice with hexane after precipitation of the proteins with ethanol. The extract was dried under nitrogen, dissolved in an ethanol-methylene chloride mixture (65:35, v / v) and injected onto a C 18 column (nucleosil; 250 mm in length, di 46 mm., Particles of 5 .mu.m). Pure methanol made it possible to elute the α-tocopherol in 5 min and the tocopherol acetate in 6.3 min at a flow rate of 2 ml / min. The compounds were detected by UV (292 nm) and then quantified by internal and external calibrations using control solutions.
Les résultats obtenus sont présentés dans le tableau suivant :The results obtained are presented in the following table:
Régime alimentaire Anovaa Diet Anova a
Amidon Fructose Amidon + FOS Fructose + FOS Sucre FOS Sucre x FOSStarch Fructose Starch + FOS Fructose + FOS Sugar FOS Sugar x FOS
Triglycérides (TG) 1,76 ± 0,21 3,73 ± 0,45 1,47 ± 0,11 2,49 ± 0,26 0,001 <0,05 NS nmol/mlTriglycerides (TG) 1.76 ± 0.21 3.73 ± 0.45 1.47 ± 0.11 2.49 ± 0.26 0.001 <0.05 NS nmol / ml
Vitamine E 9,01 ± 0,54 9,74 ± 0,92 7,21 ± 0,35 8,74 ± 0,62 NS <0,05 NS μg/mlVitamin E 9.01 ± 0.54 9.74 ± 0.92 7.21 ± 0.35 8.74 ± 0.62 NS <0.05 NS μg / ml
Vitamine E/TG 5,98 ± 0,93 2,68 ± 0,12 5,03 ± 0,29 3,95 ± 0,61 0,001 NS NS μg/mol TGVitamin E / TG 5.98 ± 0.93 2.68 ± 0.12 5.03 ± 0.29 3.95 ± 0.61 0.001 NS NS μg / mol TG
Les résultats sont les moyennes calculées pour 10 animaux ± écart-type. a valeur de p pour l'ANOVA. Les résultats de l'ANOVA sont significatifs pour p < 0,05, NS, non significatifsThe results are the means calculated for 10 animals ± standard deviation. has value of p for ANOVA. ANOVA results are significant for p <0.05, NS, not significant
Contrairement au régime amidon, le régime riche en fructose diminue le rapportUnlike the starch diet, the high fructose diet decreases the ratio
Vitamine E/TG, ce qui témoigne de l'existence du stress oxydant.Vitamin E / TG, which testifies to the existence of oxidative stress.
La supplémentation en FOS prévient la diminution de ce rapport, en d'autres termes diminue le stress oxydant résultant de la consommation du régime riche en fructose.
FOS supplementation prevents the reduction of this ratio, in other words decreases the oxidative stress resulting from the consumption of the diet rich in fructose.
REFERENCESREFERENCES
Busserolles J., Rock E., Gueux E., Mazur A., Grolier P. et Rayssiguier Y., 2002a. Short term consumption of a high sucrose diet has a pro-oxydant effect in rats. Brit. J. Nutr., 87(4) : 337-342.Busserolles J., Rock E., Gueux E., Mazur A., Grolier P. and Rayssiguier Y., 2002a. Short term consumption of a high sucrose diet has a pro-oxidant effect in rats. Brit. J. Nutr., 87 (4): 337-342.
Busserolles J., Gueux E., Rock E., Mazur A. et Rayssiguier Y., 2002b. Substituting honey for refined carbohydrates protects against the pro-oxydant effect of a high fructose diet. J Nwtr., 132(11) : 3379-82.Busserolles J., Gueux E., Rock E., Mazur A. and Rayssiguier Y., 2002b. Substituting honey for refined carbohydrates protects against the pro-oxidant effect of a high fructose diet. J Nwtr., 132 (11): 3379-82.
Lee H.S., Shoeman D.W. et Csallany A.S., 1992. Urinary response to in vivo lipid péroxydation induced by vitamin E deficiency. Lipids, 27 : 124-128.Lee H.S., Shoeman D.W. and Csallany A.S., 1992. Urinary response to in vivo lipid peroxidation induced by vitamin E deficiency. Lipids, 27: 124-128.
Okhawa H., Ohishi Ν. et Yagi K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95 : 351-358.Okhawa H., Ohishi Ν. & Yagi K., 1979. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 95: 351-358.
Rayssiguier Y., Gueux E., Bussière L., et Mazur A., 1993. Copper deficiency increases the suceptibility of lipopro teins and tissues to peroxidation in rats. J. Nutr. 123 : 1343-1348.
Rayssiguier Y., Gueux E., Bussière L., and Mazur A., 1993. Copper deficiency increases the suceptibility of lipopro teins and tissues to peroxidation in rats. J. Nutr. 123: 1343-1348.
Claims
1. Utilisation de prébiotiques pour la préparation de préparations alimentaires, d'ahcaments, ou de compositions pharmaceutiques destinés à la prévention ou au traitement du stress oxydant.1. Use of prebiotics for the preparation of food preparations, ahcaments, or pharmaceutical compositions intended for the prevention or treatment of oxidative stress.
2. Utilisation selon la revendication 1, d'au moins un oligosaccharide choisi parmi :2. Use according to claim 1, of at least one oligosaccharide chosen from:
- les fructanes - les fructo-oligosaccharides (FOS)- fructans - fructo-oligosaccharides (FOS)
- les galacto-oligosaccharides- galacto-oligosaccharides
- les xylo-oligosaccharides- xylo-oligosaccharides
- les oligosaccharides de soja- soy oligosaccharides
- les gentio-oligosaccharides - les isomalto-oligosaccharides- gentio-oligosaccharides - isomalto-oligosaccharides
3. Utilisation selon la revendication 1 ou 2, de fructo-oligosaccharides (FOS) de formule générale Glucosyl-(Fructosyl)n-Fructose ou (Fructosyl)m-Fructose où n représente un nombre entier de 1 à 8, notamment de 1 à 5, et m représente un nombre entier de 1 à 8, notamment de 1 à 5, tels que les FOS à chaîne courte 1-kestose, nystose ou fructosyl-nystose.3. Use according to claim 1 or 2, fructo-oligosaccharides (FOS) of general formula Glucosyl- (Fructosyl) n -Fructose or (Fructosyl) m -Fructose where n represents an integer from 1 to 8, in particular from 1 to 5, and m represents an integer from 1 to 8, in particular from 1 to 5, such as the short chain FOS 1-kestose, nystose or fructosyl-nystose.
4. Utilisation de prébiotiques selon l'une des revendications 1 à 3, dans le cadre de la prévention ou du traitement du stress oxydant lié à la consommation de sucres. j4. Use of prebiotics according to one of claims 1 to 3, in the context of the prevention or treatment of oxidative stress related to the consumption of sugars. j
5. Utilisation de prébiotiques selon l'une des revendications 1 à 4, dans le cadre de la prévention ou du traitement du stress oxydant lié à la consommation de fructose.5. Use of prebiotics according to one of claims 1 to 4, in the context of the prevention or treatment of oxidative stress linked to the consumption of fructose.
6. Utilisation de prébiotiques selon l'une des revendications 1 à 5, dans le cadre de la prévention ou du traitement du stress oxydant dû à une consommation de fructose alimentaire supérieure à environ 50 g/jour en moyenne. 6. Use of prebiotics according to one of claims 1 to 5, in the context of the prevention or treatment of oxidative stress due to consumption of food fructose greater than about 50 g / day on average.
7. Utilisation de prébiotiques selon l'une des revendications 1 à 6, pour laquelle lesdits prébiotiques sont administrés à une dose journalière d'environ 1 g à environ 20 g, notamment d'environ 2 g à environ 17 g, notamment d'environ 5 g à environ 15 g.7. Use of prebiotics according to one of claims 1 to 6, for which said prebiotics are administered at a daily dose of approximately 1 g to approximately 20 g, in particular approximately 2 g to approximately 17 g, in particular approximately 5 g to about 15 g.
8. Utilisation de prébiotiques selon l'une des revendications 1 à 7, en tant que composés ayant un effet antiradicalaire dans le cadre de la prévention ou du traitement du stress oxydant.8. Use of prebiotics according to one of claims 1 to 7, as compounds having an anti-free radical effect in the context of the prevention or treatment of oxidative stress.
9. Utilisation de prébiotiques selon l'une des revendications 1 à 8, en tant que composés ayant un effet anti-vieillissement lié à un effet de protection des cellules de l'organisme contre l'action des radicaux libres.9. Use of prebiotics according to one of claims 1 to 8, as compounds having an anti-aging effect linked to a protective effect of the cells of the body against the action of free radicals.
10. Préparation alimentaire comprenant un mélange de fructo-oligosaccharides (FOS), tels que définis dans la revendication 3, comprenant 64% de Glucosyl-(Fructosyl)n- Fructose et 36% de (Fructosyl)m-Fructose, de degrés de polymérisation moyens 4,8, la proportion en poids desdits FOS présents dans ladite préparation variant entre 10% et 100%, et étant notamment d'environ 15% à environ 35%o, préférablement d'environ 20%, par rapport à la quantité de fructose présent dans ladite préparation. 10. Food preparation comprising a mixture of fructo-oligosaccharides (FOS), as defined in claim 3, comprising 64% of Glucosyl- (Fructosyl) n - Fructose and 36% of (Fructosyl) m -Fructose, of degrees of polymerization means 4,8, the proportion by weight of said FOS present in said preparation varying between 10% and 100%, and being in particular from approximately 15% to approximately 35% o, preferably approximately 20%, relative to the amount of fructose present in said preparation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0216136A FR2848783B1 (en) | 2002-12-18 | 2002-12-18 | USE OF PREBIOTICS FOR PREVENTING OR TREATING OXIDIZING STRESS |
| FR0216136 | 2002-12-18 | ||
| PCT/FR2003/003770 WO2004056210A1 (en) | 2002-12-18 | 2003-12-17 | Use of prebiotics for preventing or treating oxidation stress |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1571926A1 true EP1571926A1 (en) | 2005-09-14 |
Family
ID=32406181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03813628A Withdrawn EP1571926A1 (en) | 2002-12-18 | 2003-12-17 | Use of prebiotics for preventing or treating oxidation stress |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20060252725A1 (en) |
| EP (1) | EP1571926A1 (en) |
| JP (1) | JP2006510703A (en) |
| AU (1) | AU2003300651A1 (en) |
| CA (1) | CA2510766A1 (en) |
| FR (1) | FR2848783B1 (en) |
| WO (1) | WO2004056210A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2502507A1 (en) * | 2011-03-21 | 2012-09-26 | Abbott Laboratories | Methods for improving bone health in infants using prebiotics |
| WO2013126015A1 (en) * | 2012-02-23 | 2013-08-29 | N. V. Nutricia | Composition comprising non- digestible oligosaccharides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008108651A1 (en) * | 2007-03-08 | 2008-09-12 | Friesland Brands B.V. | Infant foods with optimized amino acid composition |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE162805T1 (en) * | 1993-08-10 | 1998-02-15 | Suedzucker Ag | METHOD FOR PRODUCING INULIN DERIVATIVES |
| DE69520528T2 (en) * | 1994-06-14 | 2001-09-27 | Raffinerie Tirlemontoise, S.A. | Use of a composition containing inulin or oligofructose as an anti-cancer agent |
| JP3579128B2 (en) * | 1995-05-31 | 2004-10-20 | 明治製菓株式会社 | Lipid peroxide rise inhibitor |
| EP0879600A1 (en) * | 1997-05-20 | 1998-11-25 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Fructan containing composition for the prevention and treatment of colon cancer |
| DE19817877C2 (en) * | 1998-04-22 | 2002-06-13 | Hans Guenter Berner | Energy drink based on fruit juice |
| EP1125507A1 (en) * | 2000-02-15 | 2001-08-22 | Tiense Suikerraffinaderij N.V. (Raffinerie Tirlemontoise S.A.) | Inulin products with improved nutritional properties |
| US6774111B1 (en) * | 2000-03-14 | 2004-08-10 | Abbott Laboratories | Carbohydrate system and a method for providing nutrition to a diabetic |
| EP1174118A1 (en) * | 2000-06-28 | 2002-01-23 | Cognis France S.A. | Use of inulin and derivatives thereof |
| EP1175905A1 (en) * | 2000-07-24 | 2002-01-30 | Societe Des Produits Nestle S.A. | Nutritional Composition |
| DE20106845U1 (en) * | 2001-04-19 | 2001-11-08 | Rats-Apotheke Dr. Wolfgang Albrecht, 38678 Clausthal-Zellerfeld | Liqueur for diabetics |
| US20030004211A1 (en) * | 2001-05-25 | 2003-01-02 | Frank Corsini | Carbohydrate modifying agent and drinks containing the modifying agent |
-
2002
- 2002-12-18 FR FR0216136A patent/FR2848783B1/en not_active Expired - Fee Related
-
2003
- 2003-12-17 AU AU2003300651A patent/AU2003300651A1/en not_active Abandoned
- 2003-12-17 CA CA002510766A patent/CA2510766A1/en not_active Abandoned
- 2003-12-17 WO PCT/FR2003/003770 patent/WO2004056210A1/en active Application Filing
- 2003-12-17 JP JP2004561561A patent/JP2006510703A/en active Pending
- 2003-12-17 EP EP03813628A patent/EP1571926A1/en not_active Withdrawn
- 2003-12-17 US US10/539,632 patent/US20060252725A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008108651A1 (en) * | 2007-03-08 | 2008-09-12 | Friesland Brands B.V. | Infant foods with optimized amino acid composition |
Non-Patent Citations (1)
| Title |
|---|
| See also references of WO2004056210A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060252725A1 (en) | 2006-11-09 |
| AU2003300651A1 (en) | 2004-07-14 |
| FR2848783A1 (en) | 2004-06-25 |
| WO2004056210A1 (en) | 2004-07-08 |
| JP2006510703A (en) | 2006-03-30 |
| FR2848783B1 (en) | 2005-05-13 |
| CA2510766A1 (en) | 2004-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10016450B2 (en) | Anti-glycation methods and compositions | |
| US8465788B2 (en) | Arabinoxylans for modulating the barrier function of the intestinal surface | |
| WO2007056432A2 (en) | Compositions for regulating intestinal disorders and methods of use thereof | |
| CA2062412C (en) | Lowering blood cholesterol levels using water soluble cellulose ethers | |
| CA2489308A1 (en) | Use of taurine for the treatment of alopecia | |
| US20110130360A1 (en) | Preventing or reducing oxidative stress or oxidative cell injury | |
| WO2007063095A1 (en) | Use of zinc salts of lipoic acid for treating fat metabolism disorders | |
| CA2515290A1 (en) | Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides | |
| FR2844453A1 (en) | Food or pharmaceutical compositions for preventing onset of type II diabetes mellitus in predisposed patients, containing probiotics, preferably gluco-oligosaccharides | |
| FR2778849A1 (en) | Preventing or treating hypercholesterolemia | |
| US20220211079A1 (en) | Omega-3 Beverage | |
| CA2697125A1 (en) | Use of at least one oxime derivative of cholest-4-en-3-one as antioxidants | |
| WO2004056210A1 (en) | Use of prebiotics for preventing or treating oxidation stress | |
| WO2002039973A2 (en) | Product preparing and protecting the skin against uv radiation, countering cellular ageing and exerting an immunostimulant action | |
| JP2009120502A (en) | Chitosan-containing composition | |
| CN111315391A (en) | Composition for improving circulatory system diseases comprising tea extract having different component contents | |
| JP2005170836A (en) | Marine alga extract and lipase inhibitor containing the same | |
| KR101073624B1 (en) | Compositions comprising young Phragmites communis leaves or extracts thereof for preventing or improving obesity, or antioxidant activity | |
| EP2452577B1 (en) | Aqueous solution of phytin and use of said solution for preparing a liquid food supplement or a cosmetic composition | |
| JP2012206964A (en) | PPAR-α ACTIVITY REGULATING AGENT | |
| EP4313022A1 (en) | Nutraceutical composition comprising inulin for treating and preventing ocular disorders or intestinal microbiota imbalance | |
| Yañez-Sánchez et al. | Bio-functional activities of agavins on health | |
| CN117940141A (en) | Composition for preventing, alleviating or treating diseases associated with muscle weakness comprising celery seed extract as active ingredient | |
| WO1996038157A1 (en) | Inhibitor for lipid peroxide increase | |
| EP1406663A2 (en) | Vegetable polymer-based composition that immobilises active agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20050618 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| 17Q | First examination report despatched |
Effective date: 20070719 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20090131 |